Status:

RECRUITING

Effect of Repetitive TMS on Executive Function in Alcohol Use Disorder

Lead Sponsor:

Universidad Nacional Autonoma de Mexico

Collaborating Sponsors:

National Council of Science and Technology, Mexico

Conditions:

Alcohol Use Disorder

Eligibility:

All Genders

25-59 years

Phase:

NA

Brief Summary

Alcohol Use Disorder (AUD) is a major public health problem that affects the physical, social, family, and mental integrity of the sufferer. Behavioral self-regulation is compromised in AUD, and a ben...

Detailed Description

It is proposed that individuals predisposed to developing alcohol use disorder (AUD) exhibit alterations in executive functions, resulting from maladaptive cellular homeostatic processes and neuronal ...

Eligibility Criteria

Inclusion

  • Men and women of 25 to 59 years old
  • The reading level of at least 6th grade of primary (equivalent to fifth grade of elementary school).
  • Alcohol users with and AUDIT ≥ 20 puntos
  • Abstinence from alcohol consumption from 8 weeks to 5 years, with CIWA-Ar scale scores ≤ 9 points.
  • No disabling neuropsychiatric conditions (i.e. Schizophrenia)
  • No substance use disorders except alcohol and nicotine.
  • BrAC (Breath Alcohol) = 0.00 mg/dl in each of the assessments.
  • No traces of alcohol consumption using urine test strips.
  • No contraindications for TMS therapy.

Exclusion

  • Individuals with symptoms of severe agitation or who are unable to cooperate in the study
  • History of epilepsy
  • Sudden onset of stroke, focal neurological findings such as hemiparesis, sensory loss, visual field deficits and lack of coordination.
  • Seizures or gait disturbances
  • History of severe psychiatric disorders.
  • Alterations in a conventional electroencephalogram.
  • Pacemakers or intracranial metallic objects.
  • Elimination criteria
  • At the subject's request
  • The presence of adverse incidents that deteriorate the subject's health and would limit continuation of rTMS treatment.
  • Exacerbation of cognitive or behavioral symptoms during treatment.

Key Trial Info

Start Date :

March 16 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 1 2026

Estimated Enrollment :

44 Patients enrolled

Trial Details

Trial ID

NCT05997212

Start Date

March 16 2024

End Date

November 1 2026

Last Update

February 10 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Unidad de Resonancia Magnética

Querétaro City, Querétaro, Mexico, 76230